ID   DOT1L_HUMAN             Reviewed;        1739 AA.
AC   Q8TEK3; O60379; Q96JL1;
DT   15-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   15-NOV-2002, sequence version 2.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=Histone-lysine N-methyltransferase, H3 lysine-79 specific;
DE            EC=2.1.1.43;
DE   AltName: Full=DOT1-like protein;
DE   AltName: Full=Histone H3-K79 methyltransferase;
DE            Short=H3-K79-HMTase;
DE   AltName: Full=Lysine N-methyltransferase 4;
GN   Name=DOT1L; Synonyms=KIAA1814, KMT4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, AND
RP   MUTAGENESIS OF 163-GLY--GLY-165.
RX   PubMed=12123582; DOI=10.1016/S0960-9822(02)00901-6;
RA   Feng Q., Wang H., Ng H.H., Erdjument-Bromage H., Tempst P., Struhl K.,
RA   Zhang Y.;
RT   "Methylation of H3-lysine 79 is mediated by a new family of HMTases
RT   without a SET domain.";
RL   Curr. Biol. 12:1052-1058(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 454-1739 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [4]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Spleen;
RX   PubMed=12693554; DOI=10.1093/dnares/10.1.49;
RA   Jikuya H., Takano J., Kikuno R., Hirosawa M., Nagase T., Nomura N.,
RA   Ohara O.;
RT   "Characterization of long cDNA clones from human adult spleen. II. The
RT   complete sequences of 81 cDNA clones.";
RL   DNA Res. 10:49-57(2003).
RN   [5]
RP   INTERACTION WITH MLLT10, AND SUBCELLULAR LOCATION.
RX   PubMed=15851025; DOI=10.1016/j.cell.2005.02.020;
RA   Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L.,
RA   Xu G., Zhang Y.;
RT   "hDOT1L links histone methylation to leukemogenesis.";
RL   Cell 121:167-178(2005).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1001, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-374; SER-775; SER-1001
RP   AND SER-1009, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-374; THR-900; SER-902
RP   AND SER-1001, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-374; SER-471; THR-480;
RP   SER-775; SER-834; SER-902; SER-1001; SER-1035 AND SER-1213, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-374 AND SER-902, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-297; SER-374; SER-448;
RP   SER-775; SER-786; SER-826; SER-834; THR-900; SER-902; THR-984;
RP   SER-997; SER-1001; SER-1009; SER-1035; SER-1093; SER-1104; SER-1213
RP   AND SER-1246, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-416 IN COMPLEX WITH
RP   S-ADENOSINE-L-METHIONINE, IDENTIFICATION BY MASS SPECTROMETRY,
RP   MUTAGENESIS OF ASN-241 AND TYR-312, NUCLEOSOME BINDING, AND
RP   INTERACTION WITH DNA.
RX   PubMed=12628190; DOI=10.1016/S0092-8674(03)00114-4;
RA   Min J., Feng Q., Li Z., Zhang Y., Xu R.-M.;
RT   "Structure of the catalytic domain of human DOT1L, a non-SET domain
RT   nucleosomal histone methyltransferase.";
RL   Cell 112:711-723(2003).
CC   -!- FUNCTION: Histone methyltransferase. Methylates 'Lys-79' of
CC       histone H3. Nucleosomes are preferred as substrate compared to
CC       free histones. Binds to DNA.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000255|PROSITE-ProRule:PRU00902,
CC       ECO:0000269|PubMed:12123582}.
CC   -!- SUBUNIT: Interacts with MLLT10. {ECO:0000269|PubMed:12628190,
CC       ECO:0000269|PubMed:15851025}.
CC   -!- INTERACTION:
CC       Q03111:MLLT1; NbExp=6; IntAct=EBI-2619253, EBI-1384215;
CC       P42568:MLLT3; NbExp=4; IntAct=EBI-2619253, EBI-716132;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15851025}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=2;
CC         IsoId=Q8TEK3-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q8TEK3-2; Sequence=VSP_002228, VSP_002229;
CC         Note=No experimental confirmation available.;
CC   -!- MISCELLANEOUS: In contrast to other lysine histone
CC       methyltransferases, it does not contain a SET domain, suggesting
CC       the existence of another mechanism for methylation of lysine
CC       residues of histones.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. DOT1 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00902}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC08316.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF509504; AAM88322.1; -; mRNA.
DR   EMBL; AC004490; AAC08316.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB058717; BAB47443.1; -; mRNA.
DR   EMBL; AK074120; BAB84946.1; -; mRNA.
DR   CCDS; CCDS42460.1; -. [Q8TEK3-2]
DR   RefSeq; NP_115871.1; NM_032482.2. [Q8TEK3-2]
DR   UniGene; Hs.713641; -.
DR   PDB; 1NW3; X-ray; 2.50 A; A=1-416.
DR   PDB; 2MV7; NMR; -; B=877-900.
DR   PDB; 3QOW; X-ray; 2.10 A; A=1-416.
DR   PDB; 3QOX; X-ray; 2.30 A; A=1-416.
DR   PDB; 3SR4; X-ray; 2.50 A; A=1-351.
DR   PDB; 3SX0; X-ray; 2.28 A; A=1-420.
DR   PDB; 3UWP; X-ray; 2.05 A; A=1-420.
DR   PDB; 4EK9; X-ray; 2.50 A; A=1-416.
DR   PDB; 4EKG; X-ray; 2.80 A; A=1-416.
DR   PDB; 4EKI; X-ray; 2.85 A; A=1-416.
DR   PDB; 4EQZ; X-ray; 2.15 A; A=1-420.
DR   PDB; 4ER0; X-ray; 2.50 A; A=1-420.
DR   PDB; 4ER3; X-ray; 2.40 A; A=1-351.
DR   PDB; 4ER5; X-ray; 2.57 A; A=1-412.
DR   PDB; 4ER6; X-ray; 2.30 A; A=1-412.
DR   PDB; 4ER7; X-ray; 2.20 A; A=1-420.
DR   PDB; 4HRA; X-ray; 3.15 A; A=1-416.
DR   PDB; 4WVL; X-ray; 2.41 A; A=1-347.
DR   PDB; 5DRT; X-ray; 2.69 A; A/B=2-333.
DR   PDB; 5DRY; X-ray; 2.41 A; A/B=2-333.
DR   PDB; 5DSX; X-ray; 2.41 A; A/B=2-332.
DR   PDB; 5DT2; X-ray; 2.30 A; A/B=2-332.
DR   PDB; 5DTM; X-ray; 2.20 A; A/B=2-332.
DR   PDB; 5DTQ; X-ray; 2.61 A; A/B=2-332.
DR   PDB; 5DTR; X-ray; 2.34 A; A/B=2-332.
DR   PDB; 5JUW; X-ray; 2.28 A; A=1-420.
DR   PDB; 5MVS; X-ray; 2.18 A; A/B=2-332.
DR   PDB; 5MW3; X-ray; 2.09 A; A/B=2-332.
DR   PDB; 5MW4; X-ray; 2.19 A; A/B=2-332.
DR   PDBsum; 1NW3; -.
DR   PDBsum; 2MV7; -.
DR   PDBsum; 3QOW; -.
DR   PDBsum; 3QOX; -.
DR   PDBsum; 3SR4; -.
DR   PDBsum; 3SX0; -.
DR   PDBsum; 3UWP; -.
DR   PDBsum; 4EK9; -.
DR   PDBsum; 4EKG; -.
DR   PDBsum; 4EKI; -.
DR   PDBsum; 4EQZ; -.
DR   PDBsum; 4ER0; -.
DR   PDBsum; 4ER3; -.
DR   PDBsum; 4ER5; -.
DR   PDBsum; 4ER6; -.
DR   PDBsum; 4ER7; -.
DR   PDBsum; 4HRA; -.
DR   PDBsum; 4WVL; -.
DR   PDBsum; 5DRT; -.
DR   PDBsum; 5DRY; -.
DR   PDBsum; 5DSX; -.
DR   PDBsum; 5DT2; -.
DR   PDBsum; 5DTM; -.
DR   PDBsum; 5DTQ; -.
DR   PDBsum; 5DTR; -.
DR   PDBsum; 5JUW; -.
DR   PDBsum; 5MVS; -.
DR   PDBsum; 5MW3; -.
DR   PDBsum; 5MW4; -.
DR   ProteinModelPortal; Q8TEK3; -.
DR   SMR; Q8TEK3; -.
DR   BioGrid; 124082; 44.
DR   DIP; DIP-56410N; -.
DR   IntAct; Q8TEK3; 25.
DR   MINT; MINT-6611327; -.
DR   STRING; 9606.ENSP00000381657; -.
DR   BindingDB; Q8TEK3; -.
DR   ChEMBL; CHEMBL1795117; -.
DR   GuidetoPHARMACOLOGY; 2650; -.
DR   iPTMnet; Q8TEK3; -.
DR   PhosphoSitePlus; Q8TEK3; -.
DR   BioMuta; DOT1L; -.
DR   DMDM; 25090171; -.
DR   EPD; Q8TEK3; -.
DR   MaxQB; Q8TEK3; -.
DR   PaxDb; Q8TEK3; -.
DR   PeptideAtlas; Q8TEK3; -.
DR   PRIDE; Q8TEK3; -.
DR   Ensembl; ENST00000398665; ENSP00000381657; ENSG00000104885. [Q8TEK3-2]
DR   GeneID; 84444; -.
DR   KEGG; hsa:84444; -.
DR   UCSC; uc002lvb.4; human. [Q8TEK3-1]
DR   CTD; 84444; -.
DR   DisGeNET; 84444; -.
DR   GeneCards; DOT1L; -.
DR   HGNC; HGNC:24948; DOT1L.
DR   HPA; HPA011875; -.
DR   HPA; HPA071217; -.
DR   MIM; 607375; gene.
DR   neXtProt; NX_Q8TEK3; -.
DR   OpenTargets; ENSG00000104885; -.
DR   PharmGKB; PA134993717; -.
DR   eggNOG; KOG3924; Eukaryota.
DR   eggNOG; ENOG410XSYC; LUCA.
DR   GeneTree; ENSGT00390000013515; -.
DR   HOGENOM; HOG000143530; -.
DR   HOVERGEN; HBG051393; -.
DR   InParanoid; Q8TEK3; -.
DR   KO; K11427; -.
DR   OMA; NGLPYQS; -.
DR   OrthoDB; EOG091G00FV; -.
DR   PhylomeDB; Q8TEK3; -.
DR   TreeFam; TF106393; -.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   SIGNOR; Q8TEK3; -.
DR   ChiTaRS; DOT1L; human.
DR   EvolutionaryTrace; Q8TEK3; -.
DR   GeneWiki; DOT1L; -.
DR   GenomeRNAi; 84444; -.
DR   PRO; PR:Q8TEK3; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000104885; -.
DR   CleanEx; HS_DOT1L; -.
DR   ExpressionAtlas; Q8TEK3; baseline and differential.
DR   Genevisible; Q8TEK3; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IEA:GOC.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0042054; F:histone methyltransferase activity; IDA:MGI.
DR   GO; GO:0031151; F:histone methyltransferase activity (H3-K79 specific); IBA:GO_Central.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0006348; P:chromatin silencing at telomere; IBA:GO_Central.
DR   GO; GO:0000077; P:DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0034729; P:histone H3-K79 methylation; IDA:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0046425; P:regulation of JAK-STAT cascade; IDA:UniProtKB.
DR   GO; GO:2000677; P:regulation of transcription regulatory region DNA binding; IMP:UniProtKB.
DR   GO; GO:0032200; P:telomere organization; TAS:BHF-UCL.
DR   InterPro; IPR025789; DOT1_dom.
DR   InterPro; IPR021169; DOT1L/grappa.
DR   InterPro; IPR030445; H3-K79_meTrfase.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   PANTHER; PTHR21451; PTHR21451; 1.
DR   Pfam; PF08123; DOT1; 1.
DR   PIRSF; PIRSF037123; Histone_H3-K79_MeTrfase_met; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51569; DOT1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromatin regulator;
KW   Complete proteome; DNA-binding; Methyltransferase; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   S-adenosyl-L-methionine; Transferase.
FT   CHAIN         1   1739       Histone-lysine N-methyltransferase, H3
FT                                lysine-79 specific.
FT                                /FTId=PRO_0000186089.
FT   DOMAIN       16    330       DOT1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00902}.
FT   REGION      136    139       S-adenosyl-L-methionine binding.
FT   REGION      159    168       S-adenosyl-L-methionine binding.
FT   REGION      222    223       S-adenosyl-L-methionine binding.
FT   REGION      391    416       Required for interaction with nucleosomes
FT                                and DNA. {ECO:0000269|PubMed:12628190}.
FT   BINDING     186    186       S-adenosyl-L-methionine.
FT   MOD_RES     297    297       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     374    374       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     448    448       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     471    471       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     480    480       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     775    775       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     786    786       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     826    826       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     834    834       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     900    900       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     902    902       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     984    984       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     997    997       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1001   1001       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1009   1009       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1035   1035       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1093   1093       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1104   1104       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1213   1213       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1246   1246       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ    1537   1537       V -> N (in isoform 1).
FT                                {ECO:0000303|PubMed:12123582}.
FT                                /FTId=VSP_002228.
FT   VAR_SEQ    1538   1739       Missing (in isoform 1).
FT                                {ECO:0000303|PubMed:12123582}.
FT                                /FTId=VSP_002229.
FT   VARIANT     726    726       L -> M (in dbSNP:rs880525).
FT                                /FTId=VAR_014287.
FT   VARIANT    1386   1386       G -> S (in dbSNP:rs3815308).
FT                                /FTId=VAR_014288.
FT   VARIANT    1418   1418       V -> L (in dbSNP:rs2302061).
FT                                /FTId=VAR_014289.
FT   MUTAGEN     163    165       GSG->RCR: Abolishes methyltransferase
FT                                activity. {ECO:0000269|PubMed:12123582}.
FT   MUTAGEN     241    241       N->A,D: Loss of activity.
FT                                {ECO:0000269|PubMed:12628190}.
FT   MUTAGEN     312    312       Y->A: Loss of activity.
FT                                {ECO:0000269|PubMed:12628190}.
FT   MUTAGEN     312    312       Y->F: No effect.
FT                                {ECO:0000269|PubMed:12628190}.
FT   CONFLICT    210    210       G -> E (in Ref. 4; BAB84946).
FT                                {ECO:0000305}.
FT   CONFLICT    454    467       RSPHSPFYQLPPSV -> TLRTPSGSPRRTKL (in Ref.
FT                                3). {ECO:0000305}.
FT   CONFLICT    464    464       P -> L (in Ref. 4; BAB84946).
FT                                {ECO:0000305}.
FT   STRAND        6      9       {ECO:0000244|PDB:3UWP}.
FT   STRAND       18     23       {ECO:0000244|PDB:3UWP}.
FT   STRAND       26     28       {ECO:0000244|PDB:3UWP}.
FT   HELIX        33     47       {ECO:0000244|PDB:3UWP}.
FT   HELIX        49     54       {ECO:0000244|PDB:3UWP}.
FT   HELIX        57     62       {ECO:0000244|PDB:3UWP}.
FT   HELIX        68     90       {ECO:0000244|PDB:3UWP}.
FT   STRAND       91     93       {ECO:0000244|PDB:3UWP}.
FT   STRAND       98    100       {ECO:0000244|PDB:4ER7}.
FT   HELIX       104    118       {ECO:0000244|PDB:3UWP}.
FT   HELIX       122    124       {ECO:0000244|PDB:3UWP}.
FT   HELIX       126    128       {ECO:0000244|PDB:4EQZ}.
FT   STRAND      129    131       {ECO:0000244|PDB:3UWP}.
FT   HELIX       133    138       {ECO:0000244|PDB:3UWP}.
FT   HELIX       140    151       {ECO:0000244|PDB:3UWP}.
FT   STRAND      158    163       {ECO:0000244|PDB:3UWP}.
FT   HELIX       168    176       {ECO:0000244|PDB:3UWP}.
FT   STRAND      180    186       {ECO:0000244|PDB:3UWP}.
FT   HELIX       189    209       {ECO:0000244|PDB:3UWP}.
FT   STRAND      215    220       {ECO:0000244|PDB:3UWP}.
FT   HELIX       226    233       {ECO:0000244|PDB:3UWP}.
FT   STRAND      236    240       {ECO:0000244|PDB:3UWP}.
FT   TURN        243    245       {ECO:0000244|PDB:3QOW}.
FT   HELIX       247    257       {ECO:0000244|PDB:3UWP}.
FT   STRAND      265    270       {ECO:0000244|PDB:3UWP}.
FT   STRAND      281    283       {ECO:0000244|PDB:3UWP}.
FT   HELIX       287    289       {ECO:0000244|PDB:3UWP}.
FT   STRAND      290    295       {ECO:0000244|PDB:3UWP}.
FT   TURN        298    300       {ECO:0000244|PDB:5DTM}.
FT   STRAND      307    309       {ECO:0000244|PDB:4ER7}.
FT   STRAND      313    317       {ECO:0000244|PDB:3UWP}.
FT   HELIX       320    330       {ECO:0000244|PDB:3UWP}.
FT   HELIX       332    342       {ECO:0000244|PDB:3UWP}.
FT   STRAND      880    882       {ECO:0000244|PDB:2MV7}.
FT   TURN        885    887       {ECO:0000244|PDB:2MV7}.
SQ   SEQUENCE   1739 AA;  184853 MW;  EBA575CE3C090CAC CRC64;
     MGEKLELRLK SPVGAEPAVY PWPLPVYDKH HDAAHEIIET IRWVCEEIPD LKLAMENYVL
     IDYDTKSFES MQRLCDKYNR AIDSIHQLWK GTTQPMKLNT RPSTGLLRHI LQQVYNHSVT
     DPEKLNNYEP FSPEVYGETS FDLVAQMIDE IKMTDDDLFV DLGSGVGQVV LQVAAATNCK
     HHYGVEKADI PAKYAETMDR EFRKWMKWYG KKHAEYTLER GDFLSEEWRE RIANTSVIFV
     NNFAFGPEVD HQLKERFANM KEGGRIVSSK PFAPLNFRIN SRNLSDIGTI MRVVELSPLK
     GSVSWTGKPV SYYLHTIDRT ILENYFSSLK NPKLREEQEA ARRRQQRESK SNAATPTKGP
     EGKVAGPADA PMDSGAEEEK AGAATVKKPS PSKARKKKLN KKGRKMAGRK RGRPKKMNTA
     NPERKPKKNQ TALDALHAQT VSQTAASSPQ DAYRSPHSPF YQLPPSVQRH SPNPLLVAPT
     PPALQKLLES FKIQYLQFLA YTKTPQYKAS LQELLGQEKE KNAQLLGAAQ QLLSHCQAQK
     EEIRRLFQQK LDELGVKALT YNDLIQAQKE ISAHNQQLRE QSEQLEQDNR ALRGQSLQLL
     KARCEELQLD WATLSLEKLL KEKQALKSQI SEKQRHCLEL QISIVELEKS QRQQELLQLK
     SCVPPDDALS LHLRGKGALG RELEPDASRL HLELDCTKFS LPHLSSMSPE LSMNGQAAGY
     ELCGVLSRPS SKQNTPQYLA SPLDQEVVPC TPSHVGRPRL EKLSGLAAPD YTRLSPAKIV
     LRRHLSQDHT VPGRPAASEL HSRAEHTKEN GLPYQSPSVP GSMKLSPQDP RPLSPGALQL
     AGEKSSEKGL RERAYGSSGE LITSLPISIP LSTVQPNKLP VSIPLASVVL PSRAERARST
     PSPVLQPRDP SSTLEKQIGA NAHGAGSRSL ALAPAGFSYA GSVAISGALA GSPASLTPGA
     EPATLDESSS SGSLFATVGS RSSTPQHPLL LAQPRNSLPA SPAHQLSSSP RLGGAAQGPL
     PEASKGDLPS DSGFSDPESE AKRRIVFTIT TGAGSAKQSP SSKHSPLTAS ARGDCVPSHG
     QDSRRRGRRK RASAGTPSLS AGVSPKRRAL PSVAGLFTQP SGSPLNLNSM VSNINQPLEI
     TAISSPETSL KSSPVPYQDH DQPPVLKKER PLSQTNGAHY SPLTSDEEPG SEDEPSSARI
     ERKIATISLE SKSPPKTLEN GGGLAGRKPA PAGEPVNSSK WKSTFSPISD IGLAKSADSP
     LQASSALSQN SLFTFRPALE EPSADAKLAA HPRKGFPGSL SGADGLSPGT NPANGCTFGG
     GLAADLSLHS FSDGASLPHK GPEAAGLSSP LSFPSQRGKE GSDANPFLSK RQLDGLAGLK
     GEGSRGKEAG EGGLPLCGPT DKTPLLSGKA AKARDREVDL KNGHNLFISA AAVPPGSLLS
     GPGLAPAASS AGGAASSAQT HRSFLGPFPP GPQFALGPMS LQANLGSVAG SSVLQSLFSS
     VPAAAGLVHV SSAATRLTNS HAMGSFSGVA GGTVGGVVFN HAVPSASAHP FGARVGRGAA
     CGSATLGPSP LQAAASASAS SFQAPASVET RPPPPPPPPP PPLPPPAHLG RSPAGPPVLH
     APPPPNAALP PPPTLLASNP EPALLQSLAS LPPNQAFLPP TSAASLPPAN ASLSIKLTSL
     PHKGARPSFT VHHQPLPRLA LAQAAPGIPQ ASATGPSAVW VSLGMPPPYA AHLSGVKPR
//
